Neuropsychiatric disorders are becoming a major socioeconomic burden to modern society. In recent years, a dramatic expansion of tools has facilitated the study of the molecular basis of neuropsychiatric disorders. Molecular imaging has enabled the noninvasive characterization and quantification of biological processes at the cellular, tissue, and organism levels in intact living subjects. This technology has revolutionized the practice of medicine and has become critical to quality health care. New advances in research on molecular imaging hold promise for personalized medicine in neuropsychiatric disorders, with adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, early diagnosis, and personal health planning. In this paper, we discuss the development of radiotracers for imaging dopaminergic, serotonergic, and noradrenergic systems and β-amyloid plaques. We will underline the role of molecular imaging technologies in various neuropsychiatric disorders, describe their unique strengths and limitations, and suggest future directions in the diagnosis and management of neuropsychiatric disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085432 | PMC |
| http://dx.doi.org/10.1155/2011/439397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease.
Heliyon
January 2025
Laboratory of Brain Aging and Neurodegeneration, Fundación Instituto Leloir, IIBBA-CONICET, Av. Patricias Argentinas 435, Ciudad Autónoma de Buenos Aires, Argentina.
Inflammation and angiogenesis have been defined as potential mechanisms associated with clinical progression from a cognitively normal state to Alzheimer's disease (AD). In this observational case-control study, we aimed to determine plasma levels of cytokines as indicators of inflammation involved in cognitive decline. We measured 30 plasma proteins in 49 controls (CTL), 36 individuals with mild cognitive impairment (MCI) and 52 patients diagnosed with probable AD.
View Article and Find Full Text PDFTracing TMEM106B fibril deposition in aging and Parkinson's disease with dementia brains.
Life Med
February 2024
Department of Neurology and National Research Center for Aging and Medicine & National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Transmembrane protein 106B (TMEM106B), previously identified as a risk factor in frontotemporal lobar degeneration, has recently been detected to form fibrillar aggregates in the brains of patients with various neurodegenerative diseases (NDs) and normal elders. While the specifics of when and where TMEM106B fibrils accumulate in human brains, as well as their connection to aging and disease progression, remain poorly understood. Here, we identified an antibody (NBP1-91311) that directly binds to TMEM106B fibrils extracted from the brain and to Thioflavin S-positive TMEM106B fibrillar aggregates in brain sections.
View Article and Find Full Text PDFGinseng as a therapeutic target to alleviate gut and brain diseases via microbiome regulation.
J Ginseng Res
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
The human gut, which contains a diverse microbiome, plays an important role in maintaining physiological balance and preserving the immune system. The complex interplay between the central nervous system (CNS) and the gut microbiome has gained significant attention due to its profound implications for overall health, particularly for gut and brain disorders. There is emerging evidence that the gut-brain axis (GBA) represents a bidirectional communication system between the CNS and the gastrointestinal tract and plays a pivotal role in regulating many aspects of human health.
View Article and Find Full Text PDFA Cross-sectional Study of the Length of Stay of Persons with Mental Illnesses and Revenue to a Government Tertiary Neuropsychiatric Hospital Under Ayushman Bharat.
Indian J Psychol Med
January 2025
Psychiatric Rehabilitation Services, Dept. of Psychiatry, Bengaluru, Karnataka, India.
Background: Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is a health insurance scheme launched by the Government of India (GOI) in 2018 to cover the in-patient (IP) treatment expenditures, including mental illness treatment expenditures, for 500 million Indians. AB-PMJAY pays 100% of treatment expenditures for persons below the poverty line (BPL) and 30% for people above the poverty line (APL). Ayushman Bharat Arogya Karnataka (ABAK) trust implements this scheme in Karnataka, a southern Indian state.
View Article and Find Full Text PDFSystemic Lupus Erythematosus Presenting as Anorexia Nervosa in a Middle-Aged Woman: A Rare Case Report and Literature Review.
Immun Inflamm Dis
January 2025
Department of Internal Medicine, Al-Khor Hospital, Hamad Medical Corporation, Doha, Qatar.
Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multisystemic involvement and unclear etiology. Although SLE could be linked to multiple neuropsychiatric manifestations, the co-occurrence of anorexia nervosa was only described through a few case reports that mainly affected children and adolescents.
Case Presentation: a 40-year-old Filipina woman presented to hospital with a 3-day history of agitation, anorexia and auditory hallucinations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!